Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real-world study
In LPBC patients, the addition of carboplatin did not result in an elevated pCR rate; however, the addition of pembrolizumab tended to raise the pCR rate. In non-LPBC, the addition of carboplatin significantly increased the pCR rate, while the addition of pembrolizumab did not have the same effect.
Authors
- Sung Gwe Ahn (ORCID: https://orcid.org/0000-0002-8778-9686)
- Min Ji Kim (ORCID: https://orcid.org/0000-0002-9947-6003)
- Yoonwon Kook (ORCID: https://orcid.org/0000-0002-0756-738X)
- Joon Jeong (ORCID: https://orcid.org/0000-0003-0397-0005)
- Yoon Jin (ORCID: https://orcid.org/0000-0002-5967-4064)
- Jee Hung Kim (ORCID: https://orcid.org/0000-0002-9044-8540)
- Soong June Bae (ORCID: https://orcid.org/0000-0002-0012-9694)
- Seung Ho Baek (ORCID: https://orcid.org/0000-0003-3681-6506)
- Jung Hyun Kim (ORCID: https://orcid.org/0000-0003-4248-3760)
- Seung Eun Lee (ORCID: https://orcid.org/0009-0004-8650-5591)
- Sohyun Moon (ORCID: https://orcid.org/0009-0004-8226-6749)
Institutions
- Yonsei University (KR)
- Gangnam Severance Hospital (KR)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s13058-024-01944-0
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- National Research Foundation
- Yonsei University
- National Research Foundation of Korea
- Yonsei University College of Medicine